DocWire News Editors

DocwireNews

Since 2006, clinicians treating Waldenstrom macroglobulinemia (WM) have shifted away from using chlorambucil as first-line therapy to choosing bortezomib/dexamethasone with or without rituximab (BDR), bendamustine with or without rituximab (BR), and most recently ibrutinib, according to a study presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition.The study, presented by Ahmad Halwani, MD, of the George E. Wahlen Veterans Health Administration in Salt Lake City, was an analysis of changing practice patterns recorded in Veteran Affairs electronic health record data. Dr. Halwani and colleagues identified 505 veterans who received a diagnosis of WM and were prescribed first-line treatment for their disease between 2006 and 2018. These patients were followed until loss to follow up, death, or the end of the study period.A total of 318 patients identified in the study received a first-line treatment for WM between 2006 and 2018. The median time from WM diagnosis to treatment was 1.3 months (95% confidence interval [CI], 0.5-5.0). Overall, the median age of the patient population was 69.9 years, with the majority (73%) aged 65 years or older.First-line treatment practice patterns significantly shifted over the observation period. Patterns included de-adoption of chemotherapy and increased adoption of BDR, BR, and ibrutinib.The median immunoglobulin M was lower in patients who were treated with ibrutinib and single-agent rituximab compared with patients treated with chlorambucil with or without rituximab and BDR. The median follow-up duration was 44 months (range, 1-147 months) for all patients; however, patients treated with ibrutinib or BR had shorter follow-up periods (18 and 23 months, respectively).For all patients with WM, the median unadjusted progression-free survival was 44 months (95% CI, 37-58). The median unadjusted overall survival for this population was 94 months (95% CI, 82-117).The investigators concluded that additional research is needed &ldquo;to establish the long-term benefits and potential treatment-related toxicities of WM treatments in real-world clinical settings,&rdquo; particularly treatments that have only recently been approved/adopted for managing WM.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Analysis Finds First-Line Practice Patterns in WM Have Shifted Significantly Since 2006

ASH Annual Meeting 2020

Since 2006, clinicians treating Waldenstrom macroglobulinemia (WM) have shifted away from using chlorambucil as first-line therapy to choosing bortezomib/dexamethasone with or ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe